Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
A New Stock Exchange for Israeli Tech Companies, Backed by NYSE.
With Toronto Grabbing Some of the Best Israeli Tech Listings Away From NASDAQ, We Saw This Coming.
From...
OMNIQ (OMQS) to Begin Trading on NASDAQ
100% Here, 100% There, Pretty Soon it all Adds up. Our Sixth Client to Graduate to NASDAQ.
Yes, some...
Ronen Luzon (MYSZ) Interviewed on ILTV With Emanuelle Kadosh.
LOOKING FOR AN APP TO SOLVE YOUR ONLINE SHOPPING PROBLEMS?
What if I told you - you no longer...
Tesla (TSLA) Price Target Upped to $1,000. Passes $500 Billion in Valuation Today.
First Crossing $100 Billion in Value in January, Crossing $527 Today Puts the Valuation at $500 Billion. Why Own Anything Else?
MySize (MYSZ) in Jerusalem Post.
Israeli Start-Up MySize Eases Retail's Online Returns Problems.
While the company launched its SizeUp application in late 2015,...
OMNIQ (OMQS) Graduates to NASDAQ. And Three Wall Street Research Reports Follow.
Wall Street Brokerage Price Target Estimates of $15 - $18 Per Share.
Without disrupting legacy sales - CEO Shai...
Internet Stock Review Adds MySize (MYSZ) $0.45 to Watch List.
Short Term Turbulence Creates Potential Entry Point at $0.45.
Investors appeared to react...
OMNIQ (OMQS) Corp. Acquires Eyepax Parking Assets.
OMNIQ Corp. Acquires Eyepax USA's Intellectual Property and Technology to Establish Leadership in Multibillion Dollar Automated Parking Solutions Market
GBT (GTCH) Technologies Looking for Strategic Partners.
GBT Has Opened the Doors for Massive Potential in Minimal Infrastructure Communications.
There are some Artificial Intelligence rocket-scientists...
Latest article
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
